On Monday, Amicus Therapeutics Inc (NASDAQ: FOLD) opened lower -3.20% from the last session, before settling in for the closing price of $8.43. Price fluctuations for FOLD have ranged from $8.36 to $12.65 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 24.32%. Company’s average yearly earnings per share was noted 115.91% at the time writing. With a float of $296.87 million, this company’s outstanding shares have now reached $299.04 million.
Let’s determine the extent of company efficiency that accounts for 499 employees. In terms of profitability, gross margin is 89.98%, operating margin of 4.71%, and the pretax margin is -5.44%.
Amicus Therapeutics Inc (FOLD) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Amicus Therapeutics Inc is 3.38%, while institutional ownership is 97.64%. The most recent insider transaction that took place on Feb 19 ’25, was worth 4,000. In this transaction President and CEO of this company sold 400 shares at a rate of $10.00, taking the stock ownership to the 1,150,657 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Director proposed sale 400 for $9.85, making the entire transaction worth $3,940.
Amicus Therapeutics Inc (FOLD) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 115.91% per share during the next fiscal year.
Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators
Check out the current performance indicators for Amicus Therapeutics Inc (FOLD). In the past quarter, the stock posted a quick ratio of 2.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.33 in one year’s time.
Technical Analysis of Amicus Therapeutics Inc (FOLD)
Looking closely at Amicus Therapeutics Inc (NASDAQ: FOLD), its last 5-days average volume was 3.34 million, which is a jump from its year-to-date volume of 2.45 million. As of the previous 9 days, the stock’s Stochastic %D was 14.87%. Additionally, its Average True Range was 0.28.
During the past 100 days, Amicus Therapeutics Inc’s (FOLD) raw stochastic average was set at 4.06%, which indicates a significant decrease from 14.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.52% in the past 14 days, which was lower than the 31.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.25, while its 200-day Moving Average is $10.19. However, in the short run, Amicus Therapeutics Inc’s stock first resistance to watch stands at $8.32. Second resistance stands at $8.49. The third major resistance level sits at $8.66. If the price goes on to break the first support level at $7.98, it is likely to go to the next support level at $7.81. Should the price break the second support level, the third support level stands at $7.64.
Amicus Therapeutics Inc (NASDAQ: FOLD) Key Stats
There are currently 307,240K shares outstanding in the company with a market cap of 2.51 billion. Presently, the company’s annual sales total 528,300 K according to its annual income of -56,110 K. Last quarter, the company’s sales amounted to 149,710 K and its income totaled 14,740 K.
